Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

PDS Biotech Prioritizes PDS0301 After 71% Response Rate In Colorectal Cancer And ...

11 August 2026 · By · Wire by Fusion42

Published

11 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at pulse2.com →

◆ Verified

Fusion42 · 12 August 2026 · Fusion42 review

PDS Biotechnology is prioritizing its PDS0301 immunocytokine program after a 71% objective response rate in metastatic colorectal cancer, while discontinuing internal investment in the Phase 3 trial of PDS0101 and seeking strategic partnerships for that asset.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must refocus your oncology pipeline if you follow PDS Biotech's lead. Their shift signals tumor microenvironment-targeted therapies as the next commercial frontier in hard-to-treat cancers, opening doors for combinations that improve existing treatments.

◆ Coverage

1 source · 11 Aug 2026

◆ Related on Wire

◆ Topics

Biotechimmunotherapycolorectal-cancerclinical-trialsoncologydrug-development